Work

Supplementary Figure 4 from Tumor-Associated Antigen Burden Correlates with Immune Checkpoint Blockade Benefit in Tumors with Low Levels of T-cell Exhaustion

Year: 2026
Type: supplementary-materials
Abstract: Supplementary Figure 4. HEPA based TAB better-prioritized responders in the IC0 group of the IMVigor210 urothelial carcinoma cohort than known CTA burden (left) and FMOne tumor mutation burden (right).
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
OpenAlex ID: W7164999220
Cites:
Cited by:
Related to: 10